Blade Therapeutics

NEWS
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
FDA
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
The merger between Blade Therapeutics and Biotech Acquisition Company will provide the company with $254.3 million to drive the development of cudetaxestat.
It was yet another busy week for clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
AWARDS
  • NextGen Class of 2017
IN THE PRESS
Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, announced the presentation of positive data from Phase 1 and preclinical studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.
Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the “Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need” panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET).
Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the “Merger Agreement”), effective immediately.
Extraordinary General Meeting of BAC’s shareholders postponed until June 3, 2022 , at 10:00 a.m., Eastern Time.
Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.
Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced encouraging data from phase 1 and preclinical DDI studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.
Blade Therapeutics, Inc. today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases.
Blade Therapeutics, Inc. today announced that the company will present data for cudetaxestat in three posters at the American Thoracic Society (ATS) 2022 International Conference, May 13-18, 2022, The Moscone Center, in San Francisco.
Blade Therapeutics, Inc. announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.
Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.